ARHGDIB

Across TCGA pan-cancer cohorts, ARHGDIB RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ARHGDIB’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ARHGDIB RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGDIB is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

KIRC, THCA, and KICH are the cancer types where ARHGDIB tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGDIB RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.832	<.001	12	view →
THCA	Male	All	+1.531	<.001	10	view →
KICH	All	III,IV	−1.477	<.001	10	view →
STAD	All	II,III,IV	+1.195	<.001	8	view →
LUSC	Female	All	−1.437	<.001	6	view →
BRCA	All	All	+0.499	<.001	6	view →
LUAD	All	All	−0.369	.001	5	view →
LIHC	Female	II,III,IV	+1.025	.003	3	view →
CHOL	All	All	+1.531	.004	2	view →
ESCA	All	All	+1.456	.002	2	view →
PAAD	All	All	−1.139	.034	2	view →
UCEC	All	All	−1.060	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ARHGDIB–KIRC

Open the KIRC breakdown →